A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF VASO-OCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Registrational; Therapeutic Use
- Acronyms RESET
- Sponsors Pfizer
- 02 Aug 2019 According to a Pfizer media release, data will be submitted for presentation at a future scientific meeting.
- 02 Aug 2019 Results presented in a GlycoMimetics Media Release.
- 02 Aug 2019 According to a GlycoMimetics media release, primary endpoint (Time to readiness-for-discharge) has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History